Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland

被引:20
|
作者
Grosse, Alexandra [1 ]
Grosse, Claudia [2 ]
Rechsteiner, Markus [3 ]
Soltermann, Alex [1 ]
机构
[1] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Clin Pathol, Ramistr 100, CH-8091 Zurich, Switzerland
[2] Kepler Univ Hosp, Inst Pathol, Krankenhausstr 9, A-4021 Linz, Austria
[3] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Diagnost Mol Pathol, Ramistr 100, CH-8091 Zurich, Switzerland
关键词
Lung adenocarcinoma; EGFR; KRAS; ALK; RET; ROS1; BRAF; ERBB2; MET; PIK3CA; Non-small cell lung cancer; EML4-ALK FUSION GENE; KRAS MUTATIONS; CLINICAL CHARACTERISTICS; CANCER PATIENTS; EGFR; PIK3CA; MET; SPECTRUM; DOMAIN; TUMOR;
D O I
10.1186/s13000-019-0789-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
BackgroundMolecular testing of lung adenocarcinoma for oncogenic driver mutations has become standard in pathology practice. The aim of the study was to analyze the EGFR, KRAS, ALK, RET, ROS1, BRAF, ERBB2, MET and PIK3CA mutational status in a representative cohort of Swiss patients with lung adenocarcinoma and to correlate the mutational status with clinicopathological patient characteristics.MethodsAll patients who underwent molecular testing of newly diagnosed lung adenocarcinoma during a 4-year period (2014-2018) were included. Molecular analyses were performed with Sanger sequencing (n=158) and next generation sequencing (n=311). ALK, ROS1 and RET fusion gene analyses were also performed with fluorescence in situ hybridization and immunohistochemistry/immunocytochemistry. Demographic and clinical data were obtained from the medical records.ResultsOf 469 patients with informative EGFR mutation analyses, 90 (19.2%) had EGFR mutations. KRAS mutations were present in 33.9% of the patients, while 6.0% of patients showed ALK rearrangement. BRAF, ERBB2, MET and PIK3CA mutations and ROS1 and RET rearrangements were found in 2.6%, 1.9%, 1.9%, 1.5%, 1.7% and 0.8% of the patients, respectively. EGFR mutation was significantly associated with female gender and never smoking status. ALK translocations were more frequent in never smokers, while KRAS mutations were more commonly found in ever smokers. The association between KRAS mutational status and female gender was statistically significant only on multivariate analysis after adjusting for smoking.ConclusionThe EGFR mutation rate in the current study is among the higher previously reported mutation rates, while the frequencies of KRAS, BRAF, ERBB2 and PIK3CA mutations and ALK, ROS1 and RET rearrangements are similar to the results of previous reports. EGFR and KRAS mutations were significantly associated with gender and smoking. ALK rearrangements showed a significant association with smoking status alone.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] FREQUENCY AND SPECTRUM OF EGFR MUTATIONS IN MOROCCAN LUNG ADENOCARCINOMA PATIENTS
    Elghissassi, I.
    Inrhaoun, H.
    Boukir, A.
    Bensouda, Y.
    Mrabti, H.
    Errihani, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 432 - 432
  • [32] Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
    Li, Chenguang
    Fang, Rong
    Sun, Yihua
    Han, Xiangkun
    Li, Fei
    Gao, Bin
    Iafrate, A. John
    Liu, Xin-Yuan
    Pao, William
    Chen, Haiquan
    Ji, Hongbin
    PLOS ONE, 2011, 6 (11):
  • [33] Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC)
    Johnson, B. E.
    Kris, M. G.
    Kwiatkowski, D. J.
    Wistuba, I. I.
    Engelman, J. A.
    Pao, W.
    Rudin, C. M.
    Berry, L.
    Minna, J. D.
    Bunn, P. A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S597 - S597
  • [34] Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma The Lung Cancer Mutation Consortium Experience
    Sholl, Lynette M.
    Aisner, Dara L.
    Varella-Garcia, Marileila
    Berry, Lynne D.
    Dias-Santagata, Dora
    Wistuba, Ignacio I.
    Chen, Heidi
    Fujimoto, Junya
    Kugler, Kelly
    Franklin, Wilbur A.
    Iafrate, A. John
    Ladanyi, Marc
    Kris, Mark G.
    Johnson, Bruce E.
    Bunn, Paul A.
    Minna, John D.
    Kwiatkowski, David J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) : 768 - 777
  • [35] Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung cancer. A systematic review and meta-analysis
    Parra-Medina, Rafael
    Castaneda-Gonzalez, Juan Pablo
    Montoya, Luisa
    Gomez-Gomez, Maria Paula
    Cabezas, Daniel Clavijo
    Vargas, Merideidy Plazas
    LUNG CANCER, 2023, 185
  • [36] Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma based on real-world cumulative clinical data
    Lu, Sheng
    Guo, Aotian
    Hu, Haichuan
    Ying, Xinxin
    Li, Yao
    Huang, Zhengwei
    Xu, Wangjue
    Tao, Shen
    Hu, Xiaotong
    Yan, Na
    Zhang, Xuan
    Shen, Dan
    Sasaki, Takaaki
    Arulananda, Surein
    Onodera, Ken
    He, Zhengfu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (06) : 1296 - 1306
  • [37] Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naive Patients with Advanced Lung Adenocarcinoma
    Park, Jangchul
    Kobayashi, Yoshihisa
    Urayama, Kevin Y.
    Yamaura, Hidekazu
    Yatabe, Yasushi
    Hida, Toyoaki
    PLOS ONE, 2016, 11 (08):
  • [38] Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis
    Zhang, Yang
    Sun, Yihua
    Pan, Yunjian
    Li, Chenguang
    Shen, Lei
    Li, Yuan
    Luo, Xiaoyang
    Ye, Ting
    Wang, Rui
    Hu, Haichuan
    Li, Hang
    Wang, Lei
    Pao, William
    Chen, Haiquan
    CLINICAL CANCER RESEARCH, 2012, 18 (07) : 1947 - 1953
  • [39] Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
    Steuer, Conor E.
    Behera, Madhusmita
    Berry, Lynne
    Kim, Sungjin
    Rossi, Michael
    Sica, Gabriel
    Owonikoko, Taofeek K.
    Johnson, Bruce E.
    Kris, Mark G.
    Bunn, Paul A.
    Khuri, Fadlo R.
    Garon, Edward B.
    Ramalingam, Suresh S.
    CANCER, 2016, 122 (05) : 766 - 772
  • [40] Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma
    Dong, Yu
    Li, Ying
    Jin, Bo
    Zhang, Jie
    Shao, Jinchen
    Peng, Hong
    Tu, Shichun
    Han, Baohui
    ONCOTARGET, 2017, 8 (47) : 82244 - 82255